EUVIMEDEUVIMED entdecken
Open Access

Sustained Benefit of Blinatumomab in Infants With KMT2A -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics

Miguel Vieira Martins iD, Paola de Lorenzo iD, Rishi S Kotecha iD, Andishe Attarbaschi iD, Gabriele Escherich, Karsten Nysom iD, Jan Stary iD, Alina Ferster, Benoit Brethon, Franco Locatelli iD, Martin Schrappe iD, Peggy E Scholte-van Houtem und 4 weitere

Journal of Clinical Oncology · 10.02.2026 · 44 (5) · 370-374

DOI: 10.1200/jco-25-01806 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.02.2026. Verfasst von Miguel Vieira Martins und 15 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands. Hauptthemen laut MEDLINE: Myeloid-Lymphoid Leukemia Protein, Histone-Lysine N-Methyltransferase, Antibodies, Bispecific, Precursor Cell Lymphoblastic Leukemia-Lymphoma. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 14 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

KMT2A -rearranged infant ALL ( KMT2A -r ALL) has a poor prognosis. Adding blinatumomab, a bispecific T-cell engager targeting CD19, to standard chemotherapy for infants with KMT2A -r ALL improved short-term outcomes. Here, we present long-term results, toxicity, and pharmacokinetics of blinatumomab from this study. Thirty infants received Interfant-06 protocol chemotherapy with one additional postinduction blinatumomab course. Disease-free survival (DFS) and overall survival (OS) were compared with a historical Interfant-06–selected cohort without blinatumomab. Infection and administration of intravenous immunoglobulin (IVIg) and granulocyte-colony stimulating factor (G-CSF) were documented. Blinatumomab's steady-state concentration (Css) and clearance (CL) were analyzed. The median follow-up was 4.2 years (range, 3.2-6.0). Blinatumomab significantly improved outcomes compared with controls, with a 4-year DFS of 83.3% versus 44.0% and a 4-year OS of 93.3% versus 60.2%. No infection-related fatality occurred postinduction, in contrast to 4% in Interfant-06. IVIg was administered in 19 (63%) patients, and G-CSF in five (17%). The mean Css of blinatumomab was 706 ± 194 pg/mL/d, and the median CL was 0.89 L/h/m 2 (range, 0.57-2.66). Adding blinatumomab to standard treatment for infants with KMT2A -r ALL resulted in sustained improvement in outcome. Pharmacokinetics were comparable across pediatric age groups. The benefit of blinatumomab in frontline therapy remains promising and awaits further confirmation in ongoing trials.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Myeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseAntibodies, BispecificPrecursor Cell Lymphoblastic Leukemia-LymphomaAntineoplastic Combined Chemotherapy ProtocolsHumansInfantFemaleMaleGene RearrangementDisease-Free SurvivalTreatment Outcome

Substanzen

Myeloid-Lymphoid Leukemia ProteinHistone-Lysine N-MethyltransferaseKMT2A protein, humanblinatumomabAntibodies, Bispecific

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, the Netherlands.
  • Biostatistics and Clinical Epidemiology, Fondazione IRCCS San Gerardo dei Tintori, Monza, Italy.
  • Australian and New Zealand Children's Hematology and Oncology Group, Perth, Australia.
  • Children's Hospital and University of Western Australia, Perth, Australia.
  • Department of Pediatric Hematology and Oncology, St Anna Children's Hospital, Vienna, Austria.
  • Medical University of Vienna, and St Anna Children's Cancer Research Institute, Vienna, Austria.

ORCID-Profile: Miguel Vieira Martins, Paola de Lorenzo, Rishi S Kotecha, Andishe Attarbaschi, Karsten Nysom, Jan Stary, Franco Locatelli, Martin Schrappe, Maria G Valsecchi, Rob Pieters, Inge M van der Sluis

Zitieren

APA

Vieira Martins, M., de Lorenzo, P., Kotecha, R. S., Attarbaschi, A., Escherich, G., Nysom, K., Stary, J., Ferster, A., Brethon, B., Locatelli, F., Schrappe, M., Scholte-van Houtem, P. E., Valsecchi, M. G., Huitema, A. D. R., Pieters, R., & van der Sluis, I. M. (2026). Sustained Benefit of Blinatumomab in Infants With KMT2A -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics. Journal of Clinical Oncology, 44(5), 370-374. https://doi.org/10.1200/jco-25-01806

Vancouver

Vieira Martins M, de Lorenzo P, Kotecha RS, Attarbaschi A, Escherich G, Nysom K, et al. Sustained Benefit of Blinatumomab in Infants With KMT2A -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics. Journal of Clinical Oncology. 2026;44(5):370-374. doi:10.1200/jco-25-01806

BibTeX
@article{VieiraMartins2026,
  author = {Vieira Martins, Miguel and de Lorenzo, Paola and Kotecha, Rishi S and Attarbaschi, Andishe and Escherich, Gabriele and Nysom, Karsten and Stary, Jan and Ferster, Alina and Brethon, Benoit and Locatelli, Franco and Schrappe, Martin and Scholte-van Houtem, Peggy E and Valsecchi, Maria G and Huitema, Alwin D R and Pieters, Rob and van der Sluis, Inge M},
  title = {Sustained Benefit of Blinatumomab in Infants With KMT2A -Rearranged ALL: Long-Term Outcomes, Toxicity, and Pharmacokinetics},
  journal = {Journal of Clinical Oncology},
  year = {2026},
  volume = {44},
  number = {5},
  pages = {370--374},
  doi = {10.1200/jco-25-01806}
}
Kostenlos starten →